Instrument Inactif

Autres langues Intercept Pharmaceuticals, Inc.

Actions

ICPT

US45845P1084

Recherche biotechnologique et médicale

Autres langues

11/09/25	Intercept Pharmaceuticals, Inc. Announces Voluntary Withdrawal of Ocaliva®? for Primary Biliary Cholangitis from the US Market
12/11/24	Intercept Pharmaceuticals, Inc. Receives Complete Response Letter from FDA Addressing OCALIVA Supplemental New Drug Application
17/10/24	Intercept Pharmaceuticals, Inc. Provides Regulatory Update Regarding sNDA for OCALIVA
14/09/24	Intercept Announces Statement on FDA Advisory Committee Meeting
09/09/24	Intercept Pharmaceuticals, Inc. - Findings from COBALT Trial, Including External Control Arm, Published in The American Journal of Gastroenterology
04/06/24	Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024
20/05/24	Intercept Pharmaceuticals, Inc. Presents New Sub-Analyses of Phase 3 POISE Data Showcasing the Effect of OCA on Key Liver Biomarkers and Fibrosis in Patients with PBC at Digestive Disease Week 2024
18/05/24	Intercept Pharmaceuticals, Inc. Presents New Data Demonstrating the Impact of OCA-Bezafibrate Combination Therapy on Alp and Metabolic Outcomes After Six Months of Treatment At Digestive Disease Week®? 2024
09/05/24	Intercept Announces New PBC Data Analyses to be Presented at Digestive Disease Week® 2024 Conference
29/02/24	Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC
13/11/23	Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting® 2023
13/11/23	Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023
10/11/23	Intercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting® 2023
10/11/23	Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023
09/11/23	Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.
08/11/23	Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.
08/11/23	Alfasigma : completa con successo opa su Intercept Pharmaceuticals
08/11/23	Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from NASDAQ Composite Index
08/11/23	Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from S&P TMI Index
08/11/23	Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from S&P Global BMI Index
08/11/23	Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from S&P Biotechnology Select Industry Index
08/11/23	Alfasigma S.p.A. completed the acquisition of Intercept Pharmaceuticals, Inc..
07/11/23	Intercept: Q3 Earnings Snapshot
07/11/23	Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from NASDAQ Biotechnology Index
06/11/23	Intercept Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023